Waiv, Owkin's spin-off, raises $33M for medical AI tests
Le brief IA que les pros lisent chaque soir
Les 7 actus IA du jour, décryptées en 5 min. Gratuit.
Inclus dès l'inscription : notre sélection des meilleurs guides & comparatifs IA.
Choisis ton rythme
Gratuit · Pas de spam · Désabonnement en 1 clic
Waiv, an innovative startup spun off from the French biotech Owkin, has recently raised $33 million to advance its efforts in the field of AI-based medical testing. This funding round was co-led by OTB Ventures and Alpha Intelligence Capital, with participation from Serene Data Ventures, Karista, and SistaFund.
Founded in 2016, Owkin has established itself as a leading figure in the French startup landscape, having raised over $300 million from notable investors such as Sanofi and Cathay Innovation. Its AI-powered diagnostics and drug discovery platform laid the groundwork for Waiv.
The new entity, led by Meriem Sefta and Lionel Guillou, both former Owkin executives, focuses on enhancing medical testing, particularly for cancer detection. Waiv collaborates with pharmaceutical companies, research institutions, and healthcare providers globally to develop its medical testing platform.
According to CEO Meriem Sefta, "precision medicine only works when patients can be accurately matched with the therapies most likely to benefit them. This remains very complex to achieve." She emphasizes Waiv's ambition to make AI-powered precision testing a global standard.
The recently acquired funding will enable Waiv to strengthen its portfolio of clinical tests, deepen its partnerships in the pharmaceutical sector, and expand into new international markets. Karol Szubstarski, a partner at OTB Ventures, expressed his enthusiasm for this collaboration, stating that Waiv brings a level of technological advancement expected in the field of oncology.
Brief IA — L'actualité IA en français
L'essentiel de l'actualité de l'intelligence artificielle, décrypté et expliqué chaque jour.